产品开发转化

1.2019新型冠状病毒荧光PCR法检测技术、抗体检测技术和基因沾染检测方法转让。

1.The transfers of 2019 Novel Coronavirus Fluorescent PCR Detection Technology, Antibody Detection Technology, and Gene Contamination Detection Method Transfer.

1.1. 2020年2月，与北京卓诚惠生生物科技股份有限公司共同研发的新型冠状病毒2019-nCoV核酸检测试剂盒（荧光PCR法）获得国家医疗器械批件（国械注准20203400179），该试剂盒于2020年5月被列入世界卫生组织应急使用清单。

1.1 In February 2020, in collaboration with Beijing Applied Biological Technologies Co., Ltd., the novel coronavirus (2019-nCoV) nucleic acid detection kit (fluorescent PCR method) was granted the National Medical Device Approval (Approval No. 20203400179). By May 2020, this kit was listed in the World Health Organization's Emergency Use List (EUL).

1.2. 新型冠状病毒IgM和IgG抗体检测试剂盒成功获批，与核酸检测联合用于患者的快速诊断和筛查工作。2021年，试剂盒参加了国家“十三五”科技创新成就展。

1.2. The detection kits for the novel coronavirus IgM and IgG antibodies were approved, combined with nucleic acid tests for expedited patient diagnosis and screening. In 2021, the kit was featured in the National 13th Five-Year Plan Science and Technology Innovation Achievement Exhibition.

图.新冠病毒IgM抗体检测试剂盒

Novel Coronavirus IgM Antibody DetectionKit

图.新冠病毒IgG抗体检测试剂盒

Novel Coronavirus IgG Antibody Detection Kit

1.3.开发“新型冠状病毒（SARS-CoV-2）相关环境污染源检测试剂盒（TaqMan探针法）”，用于排除科研机构和疫苗接种场所中存在的假病毒，扩增子，疫苗株等污染，弥补现有新型冠状病毒检测方法的局限，对精准防控疫情、稳定经济社会秩序提供有力手段。

1.3. The "SARS-CoV-2 Environmental Contamination Source Detection Kit (TaqMan Probe Method)" were developed. This kit targets standard laboratory marker genes and traits of deactivated vaccines, formulating respective detection strategies that negate false viral signals, amplifications, and vaccine strains prevalent in research entities and vaccination locales. It remedies the constraints of current SARS-CoV-2 detection techniques and is instrumental for precise epidemic control and maintenance of socio-economic order.

图.新型冠状病毒（SARS-CoV-2）相关环境污染源检测试剂盒（TaqMan探针法）SARS-CoV-2

SARS-CoV-2 Environmental Contamination Source Detection Kit (TaqMan Probe Method)

2.“高效抗艾滋病病毒（HIV）多肽”相关研究成果于2016年10月与山西康宝生物制品股份有限公司签署了技术转让及合作协议书，转化金额2000万。该项目已经完成临床I期，准备进入II期临床。

2.In October 2016, the research results related to "Highly effective anti-HIV peptide" developed by researcher He Yuxian of Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, signed a technology transfer and cooperation agreement with Shanxi Kangbao Biological Products Company Limited, with an amount of 20 million. The project has completed clinical phase I and is ready to enter phase II.

3.“广谱冠状病毒膜融合抑制剂多肽药物”相关研究成果于2022年1月成功转让悦康药业集团股份有限公司，转化金额5000万。目前该项目已经完成临床I期，进入II/III期临床。

3.The research result of "Broad-spectrum Coronavirus Membrane Fusion Inhibitor Peptide Drug" developed by researcher He Yuxian of Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, was successfully transferred to Youcare Pharmaceutical Group in January 2022, with an amount of 50 million dollars. Currently, the project has completed clinical phase I and entered phase II/III.